Keytruda Clears $8 Billion and Merck Still Trades at 9.6x: Initiating at Outperform

Initiating coverage of Merck & Co., Inc. (NYSE: MRK).

Results vs. Consensus

Q3 2025 Scorecard

Consensus revenue spanned $16.98B to $17.13B across three independent providers; the $17.06B figure used here is the most widely cited. Consensus EPS was $2.36 at two of the three and $2.37 at the third. The $0.10 per-share LaNova technology-transfer milestone charge was pre-announced and sits inside both the actual and the consensus figure.

Year-over-Year Comparison (Q3 2025 vs. Q3 2024)

Operating income is gross profit less selling, general and administrative and research and development expense; the company does not present an operating-income subtotal. Business-development charges removed in the ex-BD lines are the $300M LaNova milestone in 2025 and the $2.2B EyeBio and Curon charges in 2024, and the per-share figures are the company's own stated $0.10 and $0.79 net charges.

Sequential Comparison (Q3 2025 vs. Q2 2025, GAAP basis)

The sequential table is presented on a GAAP basis because the company publishes a full quarter-by-quarter income statement on that basis but reconciles to non-GAAP only for the current quarter and the year-to-date period. Q2's 11.4% tax rate and $560M restructuring charge make the GAAP sequential comparison unusually flattering; the revenue and gross-margin lines are the ones to read.

Quality of the Beat

CAPVAXIVE's $244M also includes what the company calls an "expected seasonal inventory build," which is not separately quantified and is therefore excluded from the table above. Including it would push the identified share above half.

Revenue. The headline is 4% growth, 3% excluding foreign exchange. Two adjustments matter. First, the base: the first nine months of 2025 produced revenue of $48,611M against $48,544M a year earlier, growth of 0.1%. Q1 fell 1.6% and Q2 fell 1.9%. Q3 is the first quarter of 2025 in which Merck grew at all, and the full-year guide implies growth of 0.5% to 1.3% nominal for 2025 as a whole. Second, the composition, laid out above: strip the identified timing and one-time items and the underlying increase is closer to $305M, or 1.8%. That is not a bad number for a company absorbing the collapse of Gardasil in China, the reversion of SIMPONI marketing rights, and a 64% decline in LAGEVRIO. It is simply not a 4% number.

Margins. This is where the quarter earns its rating. Non-GAAP gross margin of 81.9% is up 142 basis points, and the company attributes it entirely to product mix, which is exactly what you would expect when Keytruda, WELIREG and WINREVAIR grow while a comparatively low-margin vaccine franchise shrinks. Operating expenses of $6,596M fell 22.4%, but that comparison is meaningless: the prior-year quarter carried $2.2B of EyeBio and Curon charges against $300M of LaNova charge this year. Strip both and expenses were $6,296M against $6,295M, flat to the dollar. The CFO's own framing was that the flat line reflects "an increase in investments in support of our robust early- and late-phase pipeline as well as key growth drivers, offset by the timing of expenses," which is a warning that the flatness is partly a phasing artifact and will not repeat. Even discounting for that, a 142-basis-point gross-margin gain against a flat expense base on 3.7% revenue growth produced ex-charge operating income growth of 10.4% and 277 basis points of ex-charge operating-margin expansion. The operating engine is working.

EPS. The reported +64% is an artifact of the prior-year charge base and should be ignored. The number to carry is $2.68 against $2.36, up 13.6%, using the company's own stated per-share charge figures in both periods. The tax rate deserves a look before crediting that growth: 13.4% against 21.9% a year ago is a large swing, and the CFO said the rate "benefited from certain discrete items." Applying the prior-year 21.9% rate to this quarter's non-GAAP pre-tax income of $7,450M would have produced roughly $2.33 of EPS, so the year-over-year tax delta is worth about $0.25 per share. Against the company's own full-year guided range of 14.0% to 15.0%, however, Q3's 13.4% is only modestly favorable, worth roughly $0.03 relative to the 14.5% midpoint. The beat versus consensus is therefore not a tax beat. It is a margin beat with a small tax tailwind on top. One footnote worth flagging: consensus of $2.36 was precisely the prior year's ex-charge base, meaning the Street had modeled zero underlying earnings growth for the quarter.

Segment Performance

Only selected products are shown, so the individual product lines do not sum to the Pharmaceutical subtotal. The Pharmaceutical, Animal Health, Other revenues and Total sales rows are the reported segment and consolidated figures and do reconcile. Total Vaccines sales, which span several of the lines above, were $3,370M against $3,675M, a decline of 8.3%.

Geographic Split

The sum of U.S. and international may differ from the global figure by a rounding dollar in the quarterly table. Mix percentages are computed from the reported regional figures.

Oncology: Keytruda passes $8 billion

Keytruda produced $8,142M, up 10% nominal and 8% excluding foreign exchange, and crossed $8B in a quarter for the first time. U.S. sales of $4,879M grew 8% and international of $3,263M grew 11%, so the growth is genuinely global rather than a U.S. pricing artifact. Management credits metastatic demand in urothelial, endometrial and gastric cancers alongside earlier-stage uptake in triple-negative breast, cervical, renal cell and non-small-cell lung cancer, plus increased use with Padcev in first-line advanced urothelial. About $100M of the U.S. growth was an extra Tuesday of shipments, which is disclosed and which reverses.

The number that matters more than the headline is the concentration. Keytruda is now 47.1% of consolidated revenue, up from 44.6% a year ago. Every quarter the franchise outgrows the rest of the company, the December 2028 exclusivity loss becomes a larger share of the problem.

"We have not given specific targets, but we see it growing as a percent overall of total sales, and it's over half of our growth."
— Robert Davis, Chairman and Chief Executive Officer, on the earlier-stage share of Keytruda

The rest of oncology grew well. WELIREG at $196M rose 42%, driven by previously treated advanced renal cell carcinoma in the U.S. plus international launches. Lynparza alliance revenue rose 12% to $379M and Reblozyl royalties rose 36% to $136M. Lenvima was flat-ish at $258M.

Assessment: The franchise is performing to plan and the earlier-stage mix is doing what the bull case requires, moving Keytruda from a metastatic drug with a hard patent date toward an adjuvant and neoadjuvant drug with a longer treatment arc. But the disclosure is thinning at exactly the moment it should be thickening: management would give a "more than 25%" figure for the earlier-stage share and nothing more granular, and declined to break out the tumor types driving it.

Vaccines: Gardasil's international business halved

Total vaccines revenue of $3,370M fell 8.3%. Gardasil is the whole story: $1,749M against $2,306M, down 24% nominal and 25% ex-FX. The split is stark. U.S. Gardasil grew 13% to $1,154M on higher net pricing and favorable public-sector purchasing. International fell 54% to $595M. Management's framing is that excluding China the franchise declined only 2% nominal and 3% ex-FX, with the residual weakness in Japan following the expiry of reimbursement for the catch-up cohort. That framing is accurate and also concedes the point: the China business has gone.

CAPVAXIVE was the offset, at $244M against $47M, of which $238M was U.S. and which includes an unquantified seasonal inventory build. VAXNEUVANCE fell 7% ex-FX on a competitive preferential recommendation in Japan. ENFLONSIA, the RSV monoclonal, recorded $79M in its first quarter, which management was explicit was stocking rather than demand.

"We had the seeding order in the third quarter. We expect that to be utilized during the fourth quarter. Feedback from customers has been very good, and we look forward to having an impact this season and much more of an impact as we go into 2026."
— Caroline Litchfield, Chief Financial Officer

Assessment: The vaccine franchise has been re-based, not repaired. Gardasil lapping China and the Japanese catch-up cohort in 2026 will flatter the optics, but the guidance management gave for the franchise was "modest growth in the near term" and it was made conditional on an ACIP dosing-schedule decision the company does not control. CAPVAXIVE and ENFLONSIA are real new assets, though $323M of combined revenue against a $557M Gardasil decline does not yet cover the hole.

Cardio-pulmonary: WINREVAIR is the cleanest launch in the portfolio

WINREVAIR delivered $360M globally, up 141%, with $335M in the U.S. The operating detail was better than the dollar figure: roughly 1,500 new U.S. patient starts and more than 24,000 total prescriptions dispensed, against a $40M drag from distributor purchase timing that the company says fully reversed in October. Adjusting for that, the underlying quarter was closer to $400M. Japan has launched. The HYPERION data presented at the European Respiratory Society showed a 76% reduction in the risk of clinical worsening in recently diagnosed patients and was published in the New England Journal of Medicine, and the FDA approved a ZENITH-based label update adding components of the clinical worsening endpoint.

OHTUVAYRE arrived with the Verona Pharma acquisition, which closed in October and therefore contributes nothing to this quarter.

Assessment: WINREVAIR is the single best evidence that Merck can launch a large product outside oncology, and the HYPERION result moves it earlier in the treatment paradigm, which is where the volume is. The label expansion and the shift toward patients not on background prostacyclin both extend the runway. This is the pillar of the post-Keytruda story that is furthest along.

Animal Health: the quiet ballast

Animal Health grew 9% nominal and 7% ex-FX to $1,615M. Livestock did the work at $1,023M, up 16% nominal and 14% ex-FX on demand across all species plus what the company calls "timing of sales." Companion Animal fell 2% to $592M on fewer vet visits and parasiticide competition, with BRAVECTO at $262M against $266M.

Assessment: Animal Health is roughly 9% of revenue and has now grown for several consecutive quarters against a pharmaceutical base that has not. It is uncorrelated with the patent cliff, the IRA and most-favored-nation policy, which makes it worth more to the equity story than its size implies. The Livestock timing benefit means the 16% is not a clean run-rate.

Key Topics & Management Commentary

Overall Management Tone: Management was measured and process-oriented rather than promotional, presenting a record revenue quarter as a data point inside a multi-year transition rather than as a headline. Confidence was highest on the pipeline, where the disclosure was specific and dated, and lowest on 2026, which was previewed only in the direction of higher spending. The one place the posture visibly tightened was U.S. pricing policy: every version of the question drew a statement of alignment with the administration's objectives and an explicit refusal to describe a framework, a timeline, or a financial effect.

1. The First Growth Quarter of 2025 Sits on a Flat Nine Months

Merck's Q3 revenue grew 3.7%. Its year-to-date revenue grew 0.1%. Q1 fell 1.6% and Q2 fell 1.9%, so the third quarter is not a continuation of anything, it is a turn. The full-year guide implies fourth-quarter revenue of $15,889M to $16,389M against $15,624M a year ago, or growth of 1.7% to 4.9%, which would make the second half the growth half and 2025 as a whole a roughly 1% growth year on a $64B base.

"We expect full year revenue to be between $64.5 billion and $65 billion. This range represents growth of 1% to 2%, excluding a negative impact from foreign exchange of approximately 0.5% using mid-October rates."
— Caroline Litchfield, Chief Financial Officer

Assessment: A 1% growth year is the correct frame for valuing this business today, and it is roughly what a 9.6x multiple implies. The investment question is not whether 2025 was a growth year. It is whether the launches now ramping convert a flat base into a growing one before December 2028 arrives.

2. Keytruda Clears $8 Billion, and Roughly $100 Million of It Is Calendar

The franchise crossed $8B in a quarter for the first time. Management disclosed, unprompted, that about $100M of the U.S. growth came from an extra Tuesday of shipments and that the fourth quarter carries a larger reversal.

"For KEYTRUDA, as previously communicated, year-over-year growth in the U.S. in the fourth quarter is expected to be negatively impacted by approximately $200 million due to the timing of wholesaler purchases."
— Caroline Litchfield, Chief Financial Officer

Assessment: Volunteering the shipping-day benefit and pre-flagging the Q4 reversal is good disclosure hygiene and the kind of thing that builds credibility for the harder disclosures still to come. It also means the $8B milestone should be discounted by roughly $100M before anyone extrapolates it.

3. QLEX Is Approved Across Every Solid Tumor Indication and Contributed Nothing Yet

The subcutaneous formulation received FDA approval in September for most solid tumor indications and in October for resectable locally advanced head and neck squamous cell carcinoma, completing coverage of every indication approved for intravenous Keytruda. The CHMP has issued a positive opinion with a European Commission decision expected in the fourth quarter. Administration takes as little as one minute. The launch began at the very end of the quarter, so the revenue contribution in Q3 is immaterial and undisclosed.

"We continue to expect that we're going to achieve 30% to 40% patient adoption and that, that will take us out to 18 to 24 months to achieve that. So nothing has changed there."
— Robert Davis, Chairman and Chief Executive Officer

Management also pre-set expectations for a slow start, tied to reimbursement mechanics rather than clinical adoption: a permanent J-code is roughly six months away, and in the interim providers working with temporary codes face longer reimbursement windows and will hesitate to order.

Assessment: This is the single most important commercial project at the company, because it is the mechanism by which a 2028 patent event becomes a partial rather than a total revenue loss. Merck has committed to a specific, falsifiable target: 30% to 40% adoption within 18 to 24 months. Nothing has been demonstrated yet. The J-code framing is a reasonable explanation for a slow first two quarters and also a ready-made excuse if the ramp disappoints. The first genuine data point arrives with the fourth quarter.

4. Gross Margin at 81.9% and Operating Expenses Flat Ex-Charge

Non-GAAP gross margin rose 142 basis points to 81.9%.

"Gross margin was 81.9%, an increase of 1.4 percentage points driven by favorable product mix. Operating expenses decreased to $6.6 billion. There were $300 million in business development charges in the quarter, compared with $2.2 billion in charges a year ago. Excluding these charges, operating expenses were flat, reflecting an increase in investments in support of our robust early- and late-phase pipeline as well as key growth drivers, offset by the timing of expenses."
— Caroline Litchfield, Chief Financial Officer

The full-year gross-margin assumption was held at approximately 82%, including an updated estimate of less than $100M of tariff-related cost, down from prior expectations.

Assessment: Both halves of the operating line delivered, and management flagged the caveat itself: some of the expense flatness is phasing, not structure. Read against the 2026 preview later on the same call, this quarter is the high-water mark for the expense ratio rather than a new baseline.

5. The Revenue Guide Narrowed Down and the EPS Guide Narrowed Up

Full-year revenue went from $64.3B to $65.3B, a $1.0B band, to $64.5B to $65.0B, a $500M band. The floor rose $200M and the ceiling fell $300M, so the midpoint declined $50M. Full-year non-GAAP EPS went from $8.87 to $8.97 to $8.93 to $8.98, lifting the midpoint $0.04 to $8.96. The tax-rate assumption came down a full point to 14.0% to 15.0%, other expense rose $100M, and the operating-expense floor rose $300M.

Assessment: The market read the revenue ceiling and reacted; the earnings midpoint went the other way. Both moves are small. The more useful observation is what sits inside the EPS raise: $0.09 of benefit from the amended Koselugo agreement, less $0.04 from Verona dilution, plus a lower tax rate and lower tariff estimate. Strip the Koselugo contract item and the operational raise is close to nil. That is a fair characterization of a quarter that was operationally good and strategically unchanged.

6. 2026 Was Previewed as a Spending Year

No 2026 guidance was given, which is normal for a third-quarter call. What was given was direction, and it was one-sided.

"As we look to 2026, we expect an acceleration in underlying operating expense growth driven by investments in both R&D and SG&A to fuel our pipeline and new launches, including more than $0.5 billion of investment to maximize the potential of OHTUVAYRE."
— Caroline Litchfield, Chief Financial Officer

On the top line the framing was "solid" growth fueled by new launches, against a named list of headwinds: DIFICID's U.S. generic entrant from mid-2025, BRIDION's loss of exclusivity partway through 2026, IRA price-setting on the JANUVIA family and a JANUVIA generic entrant midway through the year, plus ex-U.S. price pressure on Keytruda.

"We do expect continued growth in KEYTRUDA, albeit at a slightly slower pace than we've seen as we are getting to peak penetration in some of the indications, and we do expect some headwind from price in our ex-U.S. markets."
— Caroline Litchfield, Chief Financial Officer

Assessment: Only one 2026 number was quantified all call, and it was a cost: the $0.5B-plus OHTUVAYRE investment. Growth was described qualitatively while every headwind was named specifically. That asymmetry is how a company signals a flat earnings year without guiding to one, and it is the most important forward-looking content on the call.

7. Gardasil's International Business Halved

International Gardasil fell 54% to $595M. The company's ex-China framing shows a 3% ex-FX decline, which isolates China as effectively the entire problem and Japan's expired catch-up cohort as the remainder. U.S. Gardasil grew 13% on price and CDC purchasing patterns, not on volume.

"Overall, we expect modest growth for GARDASIL in the near term."
— Caroline Litchfield, Chief Financial Officer

Assessment: The 2026 comparison will look far better because the China and Japan effects annualize out, and the Street should not mistake that arithmetic for a recovery. The forward growth management described is dependent on activating a private mid-adult cohort outside the U.S., which it said "does take time," and on an ACIP dosing decision inside the U.S. Both are outside the company's control. "Modest" is doing real work in that sentence.

8. The U.S. Now Carries 58% of Revenue, and That Is the MFN Problem

Nine-month U.S. revenue grew 14% while international fell 13%, moving the mix from 49.6% U.S. a year ago to 56.3% today, and 58.0% in the third quarter alone. This happened while U.S. drug-pricing policy is unresolved and while peers were signing bilateral arrangements with the administration.

"I'm not going to give any specific updates other than to say, I am very optimistic that we're going to have a constructive outcome to those discussions. And the framework, we'll wait until we actually have something to talk about there to be more specific to how we see ours coming out."
— Robert Davis, Chairman and Chief Executive Officer

Assessment: The company's stated policy objective is higher ex-U.S. prices alongside lower U.S. patient out-of-pocket costs. Its actual revenue mix is moving the opposite way at speed, which raises the sensitivity of the P&L to whatever U.S. framework eventually lands. Merck also spent the call describing a pipeline whose launch opportunities are, in the CEO's own words, disproportionately U.S.-weighted. The concentration is a strategy, not an accident, and it is the largest un-modeled risk in the story after the cliff itself.

9. The Pipeline Delivered Its Densest Quarter of the Year

The list is long and the readouts were positive. In oncology: QLEX approval across all solid tumor indications; ESMO Presidential Symposium data from KEYNOTE-B96 in platinum-resistant recurrent ovarian cancer, with a February 20 PDUFA; KEYNOTE-905 event-free and overall survival data in cisplatin-ineligible muscle-invasive bladder cancer with an April 7 PDUFA; sac-TMT Phase 3 data from Kelun's OptiTROP-Lung04 and OptiTROP-Breast02; R-DXd Phase 2/3 REJOICE-Ovarian01 results with breakthrough therapy designation; and positive Phase 3 results for WELIREG in both LITESPARK-022 (adjuvant, with Keytruda) and LITESPARK-011 (with Lenvima). In cardiovascular: CORALreef Lipids met all primary and key secondary endpoints, the third positive Phase 3 for the oral PCSK9 inhibitor enlicitide, with detailed data due at the American Heart Association meeting. In pulmonary: HYPERION and a ZENITH-based label update. In HIV: 48-week Phase 3 data for doravirine and islatravir, and 96-week Phase 2 data for once-weekly islatravir plus lenacapavir. In immunology: three new Phase 2b trials for tulisokibart in dermatology and rheumatology. In ophthalmology: BRUNELLO enrollment complete with the primary completion date accelerated to September 2026.

"We now have approximately 80 Phase III trials underway across a diverse array of therapeutic areas, with important readouts coming over the next year in cardio-pulmonary, immunology, HIV, ophthalmology and, of course, oncology. We're investing behind more than 20 compelling launch opportunities, some already underway. These programs will transform our commercial portfolio and fuel future growth, with over $50 billion of revenue opportunity by the mid-2030s."
— Robert Davis, Chairman and Chief Executive Officer

Assessment: The $50B mid-2030s figure is not risk-adjusted and should not be treated as a forecast. What is verifiable is the cadence: more than 15 Phase 3 starts in 2025, roughly 80 trials running, and a quarter in which essentially every major readout was positive. The head of research also gave the most useful piece of scientific framing on the call, on why the TROP2 class should not be treated as fungible.

"It's very easy to sit there and say, 'Oh, this is a TROP2 ADC, and we throw all the TROP2 ADCs in a bucket as if they're not different.' I think the recent data suggests that there may be differences."
— Dean Li, President, Merck Research Laboratories

10. Business Development: "We're Not Done"

Verona Pharma closed in October, adding OHTUVAYRE, which management describes as a multibillion-dollar opportunity. The appetite for more was stated plainly and bounded.

"But as we've also said, we're not done, we do need to do more. We continue to look across all therapeutic areas... And as you think about deal size, we continue to be focused in that $1 billion to $15 billion range as the primary area. But as we've been clear to say in the past, we are willing to go larger than that, but always with the focus on science."
— Robert Davis, Chairman and Chief Executive Officer

The one thing ruled out was scale-driven consolidation.

"We do not think that a transformative acquisition, a synergy-driven deal is something that we need to do nor aligns with our future because as you know, we have one of the most robust pipelines we've ever had, and we see large synergy-driven deals as disruptive to that activity."
— Robert Davis, Chairman and Chief Executive Officer

Assessment: A $1B to $15B band with explicit willingness to exceed it, stated alongside "we do need to do more," is a clear signal that more upfront-charge acquisitions are coming. Each one distorts reported EPS in the quarter it closes, as the $300M LaNova charge and the prior year's $2.2B did. Investors modelling this company should expect the gap between reported and underlying earnings to stay wide. The refusal to consider a merger of scale is the right answer and worth crediting.

11. Capital Return Held at Roughly $5 Billion of Buyback

The dividend was $0.81 per quarter through 2025, a 3.8% yield at the reaction-day close, backed by a payout record management describes as a priority to grow over time. The repurchase commentary was more notable.

"We are maintaining our increased pace of share repurchases and expect approximately $5 billion for the full year."
— Caroline Litchfield, Chief Financial Officer

Diluted share count fell 1.7% year over year to 2,498M, and the full-year assumption is approximately 2.51B.

Assessment: Roughly $5B of buyback plus about $8B of dividends against a market capitalization near $216B is a combined shareholder yield in the 6% range. That is a meaningful part of the total-return case at this multiple, and it is being maintained while the company also funds an acquisition programme and an accelerating expense base. Watch whether the pace holds if a larger deal lands.

Guidance & Outlook

The guide includes one-time charges totalling $0.16 per share for the LaNova technology transfer and an upfront payment to Jiangsu Hengrui Pharmaceuticals, and assumes no further significant business development. Foreign exchange is a drag of approximately $0.15 per share for the year and approximately 0.5% on sales at mid-October rates.

Implied fourth quarter. Nine-month revenue of $48,611M against the $64.5B to $65.0B range implies Q4 revenue of $15,889M to $16,389M, a midpoint of $16,139M and growth of 1.7% to 4.9% against Q4 2024's $15,624M. On earnings, nine-month non-GAAP EPS of $6.93 against the $8.93 to $8.98 range implies Q4 EPS of $2.00 to $2.05 against $1.72 a year ago, growth of 16% to 19%. That base was depressed, and the quarter carries the flagged $200M U.S. Keytruda wholesaler reversal, so the apparent acceleration is less impressive than it reads.

Where the raise came from. The company itself attributes the $0.04 midpoint increase to $0.09 of benefit from the restructured Koselugo agreement, less $0.04 from the Verona acquisition, with a more favourable tax rate and lower estimated tariff costs offset by incremental foreign-exchange drag. Removing the Koselugo item, the operational raise rounds to nothing.

Guidance style. Merck has now narrowed and slightly raised its EPS range twice in succession while trimming the top of the revenue band, which is the profile of a company managing to an earnings number it is confident in and a revenue number it is not. The full-year revenue guide implies roughly 1% growth. Nothing about the guidance philosophy on this call was aggressive.

Analyst Q&A Highlights

The Shape of 2026 Revenue, Ahead of Guidance

The most consequential exchange of the call was an attempt to get the top-line pushes and pulls for next year without asking for guidance. Management answered in a structure that named every headwind precisely and every tailwind generically, which is itself the answer.

Q: "Caroline, I know you commented somewhat on expenses for 2026. I was just wondering if you can give us any comments on the top line in terms of some of the pushes and pulls as we think about that, recognizing you probably don't want to give guidance yet at this point, but just maybe help us think through some of the levers there."
— Terence Flynn, Morgan Stanley

A: "The other headwinds that we will face will be related to loss of exclusivity and generic entrants. And that really is DIFICID that's seen generic entrant halfway through 2025 in the U.S., BRIDION, which will have its LOE partway through 2026. And we also expect the headwind of IRA price setting on the JANUVIA family and the generic entrant for JANUVIA midway through next year. But overall, confident in our ability to continue to positively impact patients and drive solid growth."
— Caroline Litchfield, Chief Financial Officer

Assessment: Four named, dated, quantifiable headwinds against "solid growth" as the offsetting claim. Combined with the separately flagged acceleration in operating expense and the ex-U.S. Keytruda price pressure, this is the clearest available signal that 2026 is another transition year. The company will guide in early February; the burden of proof sits with the launches.

Subcutaneous Conversion Pace and Whether It Will Be Disclosed

A recurring line of questioning pressed on how fast intravenous Keytruda converts to the subcutaneous formulation, and, pointedly, whether investors will be able to see it. The conversion target was reaffirmed without modification, and the reporting commitment was the more valuable half of the answer.

Q: "Just back to KEYTRUDA. Could you just update us on your latest expectations for conversion from IV to subcutaneous and the kind of pace that we could expect? And with that in mind, Caroline, you made a comment on KEYTRUDA growth at a slower pace for '26. So just to check whether that is the overall franchise or IV only? And will you report the sales separately?"
— Luisa Hector, Berenberg

A: "So if you look at expectations for QLEX, as we've said, it's early in the launch, but everything appears to be on track. And there's no changes to what we previously communicated. We continue to expect that we're going to achieve 30% to 40% patient adoption and that, that will take us out to 18 to 24 months to achieve that."
— Robert Davis, Chairman and Chief Executive Officer

Assessment: The commitment to report QLEX separately from 2026 matters more than the reaffirmed target. It converts the central claim of the post-cliff bridge from a management assertion into a quarterly, checkable number. The slower-growth comment was confirmed to apply to the franchise in aggregate, not just to the intravenous formulation, which is the less comfortable of the two possible answers.

Gardasil's 2026 Recovery and What It Depends On

The franchise went essentially unmentioned in prepared remarks, which drew a direct question about whether the Street's expectation of a robust multi-year recovery is realistic. The answer conditioned U.S. growth on a regulatory decision and international growth on activating a cohort that does not yet exist.

Q: "I had a question just more on GARDASIL. Maybe it's a good thing that we haven't talked much about GARDASIL on this call, but just obviously a challenging year for that product. I'm curious how you think about that product sort of in 2026 and beyond, both in the U.S.... but also then ex-U.S., given you'll be annualizing out of the China and Japan impact. So just any sense of, I think consensus is expecting a sort of robust return to growth for that product over the next several years."
— Vamil Divan, Guggenheim Securities

A: "As we look forward for the United States, we are hopeful for growth. But clearly, as you mentioned, the ACIP recommendation around that dosing schedule will very much impact whether we do or don't grow in the United States... Overall, we expect modest growth for GARDASIL in the near term."
— Caroline Litchfield, Chief Financial Officer

Assessment: The question explicitly cited a consensus expecting a robust recovery, and the answer was "hopeful," "modest," and conditional on a committee decision. That is a considered pushback against the Street's model, delivered gently enough that it may not have registered. Anyone carrying a strong Gardasil recovery into 2026 numbers should mark it down.

Most-Favored-Nation Pricing and the Peer Precedent

With two large peers having already reached arrangements with the administration, the obvious question was whether those deals form a template and where Merck stands. The answer contained no framework, no timing and no financial sizing.

Q: "Just Rob, a question on MFN. I appreciate the color in the prepared remarks. But just following some of the recent deals with the administration, both with Pfizer and Astra, should we be thinking about this type of structure as a reasonable framework for the industry? And just any updates in terms of where Merck is in terms of its discussion with the administration on MFN."
— Christopher Schott, JPMorgan

A: "We are in continuing discussions with the administration. I'm not going to give any specific updates other than to say, I am very optimistic that we're going to have a constructive outcome to those discussions. And the framework, we'll wait until we actually have something to talk about there to be more specific to how we see ours coming out."
— Robert Davis, Chairman and Chief Executive Officer

Assessment: A non-answer, though a defensible one while negotiations are live. The information content is in the tone: optimistic, and unwilling to confirm that the peer structures are the template. For a company with 58% of its quarterly revenue in the United States and rising, this is the largest unquantified variable in the model after the patent cliff, and it will stay unquantified until an agreement is signed.

Whether the U.S. Revenue Mix Keeps Rising

A separate line of questioning approached the same policy exposure from the revenue side, asking where the geographic split lands in five years and how much of the change is product mix versus price equalisation. Management confirmed the direction and declined to quantify either component.

Q: "If we look at kind of Merck's ratio of revenue today, it's about 50-50 inside the U.S. versus outside the U.S. How different do you expect that to be in 5 years' time? And how much of that could be attributed to product mix? And how much down to kind of equalization of price?"
— Courtney Breen, Bernstein

A: "A lot of those opportunities disproportionately will be U.S. based, primarily just because of the nature of the drugs and the uptakes and the value you can assert to the U.S. market. So mix will affect how we look forward. How MFN or other pricing dynamics change, it's too early to say because we need to see what it is. And so I would leave it at that for right now."
— Robert Davis, Chairman and Chief Executive Officer

Assessment: The premise of the question was already stale. The mix was 50-50 last year; nine-month 2025 is 56/44 and the quarter alone was 58/42. Management confirmed the pipeline will push it further in the same direction. Concentrating revenue in the one market whose pricing regime is actively being renegotiated is a deliberate bet that the renegotiation ends acceptably.

Business Development Appetite and Deal Size

The opening question probed how much more dealmaking is coming and whether industry consolidation talk changes the approach. The response set an explicit size band and ruled out one category entirely.

Q: "Maybe for Rob on BD. I was reassured to hear in the prepared remarks that you are assessing potential targets with urgency. And certainly, your Verona deal seems well received, and it seems that the market wants to see more of those types of transactions from you. So I guess any updated framing on what you're looking for would be helpful."
— Asad Haider, Goldman Sachs

A: "As you think about deal size, we continue to be focused in that $1 billion to $15 billion range as the primary area. But as we've been clear to say in the past, we are willing to go larger than that, but always with the focus on science and always understanding that if we look and see an opportunity, we're going to do it based on that unmet need."
— Robert Davis, Chairman and Chief Executive Officer

Assessment: Useful and unusually specific. A stated $1B to $15B primary band with explicit willingness to exceed it, paired with "we do need to do more," should be modelled as a recurring drag on reported EPS rather than a one-off. The categorical rejection of synergy-driven consolidation is the right instinct and removes the largest capital-allocation tail risk from the story.

The Earlier-Stage Share of the Keytruda Franchise

A question sought the proportion of Keytruda revenue now coming from earlier-stage settings and which of the ten approved earlier-stage indications drive it. The proportion was given loosely; the breakdown was not given at all.

Q: "I wonder if you could give us an update on KEYTRUDA and the proportion of the sales that you have from early-stage settings and a breakdown of which of those tumor types of the 10 approved is driving that revenue?"
— Daina Graybosch, Leerink Partners

A: "We have not given specific targets, but we see it growing as a percent overall of total sales, and it's over half of our growth. So it is an important driver, especially as we think about the QLEX launch that is just starting to get underway."
— Robert Davis, Chairman and Chief Executive Officer

Assessment: "Exceeding 25%" and "over half of our growth" are the only two quantities offered, against a 2024 commitment to reach 25%. The earlier-stage mix is the second pillar of the cliff defence after QLEX, because adjuvant and neoadjuvant use is stickier and harder for a biosimilar to displace. It deserves the same disclosure discipline the company just committed to for QLEX, and it is not getting it.

The RSV Launch and What the First Revenue Actually Is

Questioning on the new RSV antibody drew a clarification that the entire first-quarter figure was channel fill rather than administered doses, alongside an acknowledgement that approval landed later than planned relative to the season.

Q: "I wanted to just touch on the ENFLONSIA launch in the United States. Heading into RSV season, can you just talk about the initial feedback, say, versus the competition and kind of what you're seeing in terms of potential uptake as we head into RSV season."
— Evan Seigerman, BMO Capital Markets

A: "If you look at how that launch has progressed, I would point out that while we did receive, obviously, all the full approvals we were a couple of weeks later than initially expected. So that did play into this because it put us a little bit later into the season."
— Robert Davis, Chairman and Chief Executive Officer

Assessment: Candid, and the candour is the point. The $79M is a seeding order, the launch started late in the season, and no share, script or competitive-conversion data was offered. Treat the RSV franchise as a 2026 story and do not annualise the first print.

What They're NOT Saying

1. Any quantification of the 2028 Keytruda trough: Keytruda is 47.1% of quarterly revenue and loses U.S. exclusivity in December 2028. Across prepared remarks and thirteen questions, no revenue erosion estimate, duration, or range was offered. The word "cliff" was not used by management once.
2. A 2026 operating-expense number: Management explicitly flagged "an acceleration in underlying operating expense growth" and then quantified exactly one component, the $0.5B-plus for OHTUVAYRE. A directional cost warning without a magnitude is the least useful form of guidance and the one that most often precedes a disappointing February.
3. Any QLEX revenue or conversion data: The product was approved in September and launched at the end of the quarter, so a small number would be defensible. Instead, no number at all was given, and the reaffirmed 30% to 40% target rests on no disclosed evidence. The separate-reporting commitment starts in 2026, which means investors will not see the ramp for two more quarters.
4. A most-favored-nation framework, timeline, or financial effect: Two peers had already signed. Merck offered optimism and nothing else, four separate times.
5. The China Gardasil run-rate: The company discloses growth "excluding China" but has never disclosed what the China business now is. Investors cannot tell whether the decline has bottomed, and therefore cannot judge the 2026 lapping benefit.
6. What $676M of year-to-date restructuring charges is buying: Restructuring costs are excluded from non-GAAP entirely, and neither the release nor the call quantifies the run-rate savings those charges generate or when they appear in the expense base. Nine months of charges with no stated return is a gap.
7. ENFLONSIA demand, share, or competitive conversion: Only the $79M stocking figure was given. No script data, no comparison against the incumbent, no view on how much of the seeding order converts.
8. The magnitude of the ex-U.S. Keytruda pricing headwind: Named as a 2026 factor and left unsized, in the same breath as a comment that international Keytruda grew 11% this quarter. Those two statements are difficult to reconcile without a number.

Market Reaction

• Pre-print setup: MRK closed at $86.58 on October 29. The stock was down 13.0% year to date against the S&P 500's 17.2% gain, down 17.4% over twelve months, and up 3.2% over the trailing thirty days. The 52-week closing range was $73.47 to $104.83, placing the pre-print close 17.8% above the low and 17.4% below the high.
• Reaction session (October 30, a before-the-open report): Opened at $84.62, down 2.3%. Traded as low as $83.30, down 3.8%, and as high as $87.30, up 0.8%. Closed at $86.28, down 0.3% or $0.30.
• Volume: 16.7M shares against a 30-day average of 12.3M, or 1.4 times normal.
• Index comparison: The S&P 500 fell 1.0% on the same session, so MRK finished roughly 0.7 percentage points ahead of the market on its own earnings day.

The gap down was a guidance reaction, not a results reaction. The only negative item in the release was the top of the full-year revenue range coming down $300M, which moved the midpoint $50M lower, and the wire coverage keyed on exactly that. The narrowed sales view was the headline; the raised earnings midpoint was not.

What happened next is the more interesting half. From the 9:00 a.m. call onward the stock recovered nearly the entire gap, closing just $0.30 below the prior session and within $1.02 of the session high. Investors who read past the revenue band found an 81.9% gross margin, an expense base flat to the dollar excluding business-development charges, Keytruda through $8B, and an earnings guide that went up. On a day the index fell 1%, that combination was enough to close ahead of the market.

The setup is what makes the muted reaction notable rather than dull. MRK entered this print having trailed the S&P by roughly thirty points year to date and having spent 2025 recovering from a low in the low $70s. A stock that has already de-rated does not need good news to stop falling; it needs the absence of new bad news. This quarter supplied that, and the reaction was a stock that stopped going down rather than one that went up. At the closing price the shares change hands at 9.6 times the raised full-year earnings guide midpoint, with a 3.8% dividend yield attached.

Street Perspective

Debate: Is a sub-10x multiple a value opportunity or an accurate discount for 2028?

Bull view: The bull case being made on the Street is that 9.6 times current-year earnings on a franchise generating 82% gross margins and roughly 6% of combined dividend and buyback yield is too cheap for a risk that is three years out and partially mitigated by an approved subcutaneous formulation, an earlier-stage indication mix that is already above 25% of the franchise, and roughly 80 running Phase 3 programmes. Multiple compression of this depth typically overshoots.

Bear view: The bear camp contends that the multiple is not an error but a correct present value. Roughly 47% of revenue faces a hard U.S. date, the base business grew 0.1% over nine months, 2026 carries a named loss-of-exclusivity stack alongside an explicitly accelerating expense base, and management has never put a number on the trough. A cheap multiple on an asset whose earnings are about to step down is not cheap.

Our take: The bears have the better description of the business and the bulls have the better description of the price. The relevant horizon for a twelve-month rating ends in late 2026, well before the exclusivity date, and across that window the shareholder yield alone is roughly 6% while the pipeline events that would change the terminal-value debate are dated and dense. We think the risk-adjusted setup favours ownership, with the caveat that this is a total-return case rather than a growth case.

Debate: Does the subcutaneous conversion actually solve anything?

Bull view: Some sell-side desks argue that 30% to 40% patient adoption within 18 to 24 months converts a large slice of the franchise onto a formulation with its own intellectual-property position and a genuine convenience advantage, administered in as little as one minute versus an infusion chair. Approval now covers every indication approved for the intravenous product, and the company will begin disclosing the split next year.

Bear view: Skeptics note that the target is a management assertion supported by no data whatsoever as of this call, that a permanent J-code is six months away and reimbursement friction will suppress the early ramp, and that a conversion which merely shifts revenue between formulations does not create new revenue. The economics of the converted units, and how much of that value ultimately accrues to Merck rather than to payers and providers, have not been laid out.

Our take: The bears are right that nothing has been proven and the bulls are right that the mechanism is real and now approved. The decisive fact is the commitment to report QLEX separately from 2026, which converts an assertion into a series of checkable quarterly numbers. Until two or three of those numbers exist, this should be treated as an option rather than an asset.

Debate: Is 2026 a growth year or a second transition year?

Bull view: A growing consensus view is that the launch cohort finally reaches critical mass in 2026: WINREVAIR annualising off a $360M quarter and expanding into earlier-diagnosed patients on the HYPERION data, CAPVAXIVE in its second full year, ENFLONSIA in a full RSV season, OHTUVAYRE newly acquired, plus Gardasil lapping the China and Japan collapse. Together those should more than cover the loss-of-exclusivity stack.

Bear view: The bear camp points out that management named the headwinds specifically and the tailwinds generically, that Keytruda growth was pre-guided to slow, that the only 2026 figure the company quantified all call was an incremental half-billion dollars of spending, and that Gardasil's own guidance was "modest growth" contingent on an ACIP decision. A revenue year that grows while the expense base accelerates is a flat earnings year.

Our take: We side with the bears on 2026 earnings and with the bulls on 2026 revenue, which is the same conclusion by a different route: another transition year. That is already reflected at 9.6x. The mistake would be paying a growth multiple for it, and nobody is being asked to.

Debate: Does rising U.S. revenue concentration make Merck more or less exposed to policy?

Bull view: The optimistic reading is that the U.S. mix is rising because Merck is winning in the market that pays for innovation, that the company's stated policy position aligns with the administration's objectives on out-of-pocket costs and international price equalisation, and that a negotiated outcome removes an overhang the stock has already discounted.

Bear view: The skeptical reading is that going from 49.6% to 56.3% U.S. revenue in nine months, while the U.S. pricing regime is being renegotiated and two peers have already signed bilateral arrangements, concentrates rather than diversifies risk, and that management's inability to describe any framework this late suggests the terms are not settled.

Our take: The concentration is a deliberate consequence of a pipeline weighted toward products with U.S.-heavy economics, which management said plainly. That is a defensible strategy and an undeniable increase in single-jurisdiction policy exposure. We would not underwrite a specific outcome here, but we note that the current multiple is not paying for a good one.

Model Update Needed

Valuation. At the $86.28 reaction close and the raised full-year guide midpoint of $8.955, MRK trades at 9.6 times current-year earnings with a 3.8% dividend yield on the $3.24 annualised rate. We set fair value at $98 to $112, equivalent to 11.0 to 12.5 times that midpoint, which implies 13.6% to 29.8% price upside plus the dividend. The upper bound of that range sits marginally above where the shares traded twelve months ago and well below the multiple this business carried before the cliff entered the debate, so the range assumes partial rather than full normalisation. The bear case is not a lower multiple, which is already at a decade low; it is a lower earnings base in 2028 and 2029, which nobody can size until management does.

Thesis Scorecard Post-Earnings

This is the initiation, so the pillars below are established rather than graded. Each will be scored against subsequent quarters.

Overall: Thesis established. The operating engine is in better shape than the top line suggests, the pipeline is delivering on cadence, and the two structural risks (the 2028 exclusivity loss and a flat base carrying rising spend) are real and unquantified by management. The distinguishing feature of the setup is that the price already reflects most of the pessimism.

Action: Buy. At 9.6 times current-year earnings with a 3.8% dividend yield and roughly a 6% combined shareholder yield, against an index the stock has trailed by about thirty points year to date, the twelve-month risk and reward favour ownership. We would turn more constructive still on two specific developments: the first two quarters of disclosed QLEX conversion data showing the ramp tracking toward 30% to 40%, and any credible quantification of the 2028 to 2030 revenue trough. We would step back on a multiple above roughly 13 times without those, or on evidence that the 2026 expense acceleration is larger than the launch contribution.